We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · September 01, 2020

Talazoparib vs Chemotherapy in Germline BRCA1/2-Mutated HER2-Negative Advanced Breast Cancer

Annals of Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Annals of Oncology
Talazoparib Versus Chemotherapy in Patients With Germline BRCA1/2-Mutated HER2-Negative Advanced Breast Cancer: Final Overall Survival Results From the EMBRACA Trial
Ann. Oncol 2020 Aug 20;[EPub Ahead of Print], JK Litton, SA Hurvitz, LA Mina, HS Rugo, KH Lee, A Gonçalves, S Diab, N Woodward, A Goodwin, R Yerushalmi, H Roché, YH Im, W Eiermann, RGW Quek, T Usari, S Lanzalone, A Czibere, JL Blum, M Martin, J Ettl

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading